BACKGROUND AND PURPOSE: Cisplatin-based chemo-irradiation (CRT) is increasingly used for head and neck squamous cell carcinoma (HNSCC). We aimed to assess hearing deterioration due to low-dose cisplatin chemoradiation and to compare the observed hearing loss with hearing loss in our previously described high-dose cisplatin CRT cohort. MATERIALS AND METHODS: A prospective analysis of hearing thresholds at low and (ultra)-high frequencies obtained before and after treatment in 60 patients. Patients received low-dose cisplatin (6mg/m(2), daily infusions, 20-25 days) with concomitant accelerated radiotherapy (70Gy). RESULTS: Audiometry up to 16kHz was performed before therapy and 31 days (median) post-treatment. The total incidence of ototoxicity in CTCAEv3.0 was 31% in audiograms up to 8kHz, and 5% of ears tested qualified for HAs due to treatment. The mean hearing loss at speech frequencies was 2.6dB (SD 5.7) and 2.3dB (SD 9.2) at PTA 1-2-4kHz air-conduction and bone-conduction, respectively. The mean hearing loss at ultra-high frequencies (PTA AC 8-10-12.5kHz) was 9.0dB (SD 8.1). Low-dose cisplatin CRT caused less acute hearing loss (CTCAE 31%), compared to high-dose cisplatin CRT (CTCAE 78%). CONCLUSIONS: Low-dose cisplatin chemo-irradiation for HNSCC is a relatively safe treatment protocol with respect to ototoxicity.
BACKGROUND AND PURPOSE:Cisplatin-based chemo-irradiation (CRT) is increasingly used for head and neck squamous cell carcinoma (HNSCC). We aimed to assess hearing deterioration due to low-dose cisplatin chemoradiation and to compare the observed hearing loss with hearing loss in our previously described high-dose cisplatin CRT cohort. MATERIALS AND METHODS: A prospective analysis of hearing thresholds at low and (ultra)-high frequencies obtained before and after treatment in 60 patients. Patients received low-dose cisplatin (6mg/m(2), daily infusions, 20-25 days) with concomitant accelerated radiotherapy (70Gy). RESULTS: Audiometry up to 16kHz was performed before therapy and 31 days (median) post-treatment. The total incidence of ototoxicity in CTCAEv3.0 was 31% in audiograms up to 8kHz, and 5% of ears tested qualified for HAs due to treatment. The mean hearing loss at speech frequencies was 2.6dB (SD 5.7) and 2.3dB (SD 9.2) at PTA 1-2-4kHz air-conduction and bone-conduction, respectively. The mean hearing loss at ultra-high frequencies (PTA AC 8-10-12.5kHz) was 9.0dB (SD 8.1). Low-dose cisplatin CRT caused less acute hearing loss (CTCAE 31%), compared to high-dose cisplatin CRT (CTCAE 78%). CONCLUSIONS: Low-dose cisplatin chemo-irradiation for HNSCC is a relatively safe treatment protocol with respect to ototoxicity.
Authors: Stephanie M Cohen; Ridhwi Mukerji; Shuang Cai; Ivan Damjanov; M Laird Forrest; Mark S Cohen Journal: Am J Surg Date: 2011-10-08 Impact factor: 2.565
Authors: Arslan Babar; Neil M Woody; Ahmed I Ghanem; Jillian Tsai; Neal E Dunlap; Matthew Schymick; Howard Y Liu; Brian B Burkey; Eric D Lamarre; Jamie A Ku; Joseph Scharpf; Brandon L Prendes; Nikhil P Joshi; Jimmy J Caudell; Farzan Siddiqui; Sandro V Porceddu; Nancy Lee; Larisa Schwartzman; Shlomo A Koyfman; David J Adelstein; Jessica L Geiger Journal: Curr Oncol Date: 2021-06-30 Impact factor: 3.677
Authors: Laura Astolfi; Sara Ghiselli; Valeria Guaran; Milvia Chicca; Edi Simoni; Elena Olivetto; Giorgio Lelli; Alessandro Martini Journal: Oncol Rep Date: 2013-02-06 Impact factor: 3.906